Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial – Authors' reply

Key Points

• The aim is to evaluate the effects of semaglutide on weight loss and cardiovascular outcomes.
• Conducted as a randomized trial
• Focused on participants with obesity
• Analyzed cardiovascular outcomes associated with weight loss interventions.
• Semaglutide led to significant weight loss versus control; exact weight loss values not detailed.
• Improved cardiovascular risk markers were observed in the semaglutide group.
• Positive effects on health measures indicate potential for broader applications.